We are live on
!
Find out more
SPPAM
Summit Partners Public Asset Management Portfolio holdings
AUM
$5.69B
1-Year Est. Return
259.25%
This Fund
S&P 500
This Quarter
Est. Return
+26.46%
1 Year Est. Return
+259.25%
3 Year Est. Return
+1,166.96%
5 Year Est. Return
+1,972.9%
10 Year Est. Return
+39,131.91%
AUM
$4.81B
AUM Growth
-$10.4M
(-0.22%)
Cap. Flow
+$15.6M
Cap. Flow
% of AUM
0.32%
Top 10 Holdings %
Top 10 Hldgs %
27.78%
Holding
221
New
56
Increased
28
Reduced
33
Closed
97
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Guardant Health
GH
|
+$66.4M |
| 2 |
Natera
NTRA
|
+$59.3M |
| 3 |
CDTX
Cidara Therapeutics
CDTX
|
+$56.2M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$53.7M |
| 5 |
Credo Technology Group
CRDO
|
+$45.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VRNA
Verona Pharma
VRNA
|
+$191M |
| 2 |
Commault Systems
CVLT
|
+$74.9M |
| 3 |
Mercado Libre
MELI
|
+$42.5M |
| 4 |
TSMC
TSM
|
+$37.8M |
| 5 |
WAY
Waystar Holding Corp
WAY
|
+$33.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.44% |
| 2 | Miscellaneous | 26.08% |
| 3 | Healthcare | 21.85% |
| 4 | Industrials | 8.52% |
| 5 | Communication Services | 5.11% |
Similar funds
BCM
CIA
JCM
ASC
ECM
BPWM
KKRC
CTB
Summit Partners Public Asset Management's Q4 2025 Portfolio in Review
As of Q4 2025, Summit Partners Public Asset Management held 221 positions worth $4.81B, down 0.22% from $4.82B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Summit Partners Public Asset Management's Q4 2025 filing shows 56 new, 28 increased, 33 reduced and 97 closed positions. Its largest new stake was SiTime: 123,958 shares worth $43.8M. The largest sale was Verona Pharma, an estimated $191M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 26% a quarter earlier, followed by Miscellaneous and Healthcare.
- Summit Partners Public Asset Management's largest Q4 2025 buy was SiTime: 123,958 shares worth $43.8M.
- Summit Partners Public Asset Management added most to Guardant Health in Q4 2025, an estimated $66.4M increase.
- Summit Partners Public Asset Management's biggest Q4 2025 reduction was TSMC, cutting an estimated $37.8M.
- Summit Partners Public Asset Management fully exited Verona Pharma in Q4 2025, selling an estimated $191M.
- Summit Partners Public Asset Management's ten largest holdings make up 28% of its $4.81B portfolio in Q4 2025.
- Summit Partners Public Asset Management opened 56 new positions and closed 97 in Q4 2025.
- Summit Partners Public Asset Management's portfolio value fell 0.22% quarter-over-quarter to $4.81B.
Based on Summit Partners Public Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.